Gut Inflammation & Colorectal Cancer Risk: Epigenetic Memory Explained

Chronic gut inflammation doesn’t simply resolve when the triggering event subsides. New research, funded by the National Institutes of Health (NIH), reveals that inflammation leaves a lasting “memory” within the epigenome of gut stem cells, potentially increasing the risk of colorectal cancer long after recovery. This discovery sheds light on the long-understood link between inflammatory bowel disease and cancer, pinpointing a molecular mechanism that could open avenues for earlier detection and preventative therapies.

The Epigenetic Echo of Inflammation

For some time, clinicians have observed a heightened risk of colorectal cancer in individuals with a history of chronic colitis, even after symptoms have resolved. The new study, conducted by researchers at the Broad Institute of MIT and Harvard, sought to understand how this increased risk persists. Using a mouse model of chronic colitis, the team tracked changes within the colon during inflammation and the subsequent recovery period. They found that repeated cycles of gut injury spurred increased activity of AP-1 transcription factors – proteins that play a crucial role in regulating gene expression – and ultimately promoted tumor growth.

But the key finding wasn’t simply the increased AP-1 activity. It was the discovery that this activity left a lasting mark on the epigenome of colonic stem cells. The epigenome, unlike our DNA sequence, is dynamic. It consists of chemical modifications to our genome that influence which genes are turned on or off, without altering the underlying DNA code itself. Consider of it as a set of instructions *about* the instructions in our DNA. This flexibility allows cells to adapt to changing conditions, like inflammation, by adjusting gene expression to promote healing, and regeneration. However, this adaptability can have unintended consequences.

“We have known for some time that colitis can accelerate tumor growth after cancer has already begun, but here we display that the effect of chronic inflammation on cancer risk remains well after animals have recuperated,” explained Jason Buenrostro, PhD, corresponding author of the study and a member of the Broad Institute and professor at Harvard University, in a statement released by the NIH.

Stem Cell Memory and Cancer Risk

The researchers discovered that the epigenetic changes triggered by colitis were inherited by new cells as stem cells divided – effectively creating a “memory” of the inflammation that persisted for over 100 days after the colitis-inducing chemicals were removed. To confirm this, they developed a method to track these epigenetic memories within organoids – miniature, lab-grown versions of the colon built from injured mouse tissue. This confirmed that the altered activity of AP-1 was indeed passed down through generations of colonic stem cells.

To assess the impact on cancer risk, the researchers introduced genes known to promote tumor growth into mice that had either recovered from chronic colitis or were previously healthy. The results were striking: tumor growth was significantly faster in the mice with a history of colitis. Further investigation revealed that the regenerative activities associated with AP-1 were in overdrive within the tumors of the recovered animals. Blocking AP-1 activity effectively eliminated the pro-cancer effect of prior colitis, suggesting it’s a central player in linking chronic gut inflammation to increased cancer risk.

What Does This Mean for Humans?

While this research was conducted in mice, the implications for human health are significant. Colorectal cancer is the third most common cancer diagnosed in the United States, according to the American Cancer Society. And the link between chronic inflammatory conditions, such as ulcerative colitis and Crohn’s disease, and an increased risk of colorectal cancer is well-established. (See Crohn’s & Colitis Foundation for more information on inflammatory bowel disease and cancer risk.)

The study suggests that the risk isn’t solely determined by the presence of active inflammation, but by the lasting epigenetic changes it induces in gut stem cells. This raises the possibility of identifying individuals at increased risk even *after* their inflammatory condition has been brought under control. Buenrostro and his colleagues hypothesize that tests to detect these epigenetic memories could potentially inform early evaluation strategies.

Understanding Epigenetics: A Simplified View

Epigenetics is a relatively new field of study, and the mechanisms are complex. Essentially, epigenetic changes don’t alter the DNA sequence itself, but rather affect how genes are read and expressed. These changes can be influenced by a variety of factors, including diet, lifestyle, and environmental exposures. The dynamic nature of the epigenome means that these changes aren’t necessarily permanent, and there’s growing interest in developing therapies that can “reprogram” the epigenome to restore healthy gene expression patterns.

The Path Forward: From Research to Potential Therapies

The researchers emphasize that further investigation is needed to determine whether these findings translate to humans. However, the identification of AP-1 as a key mediator of the link between chronic inflammation and colorectal cancer opens up new avenues for therapeutic intervention. Disrupting the post-colitis activity of AP-1 could potentially stall tumor growth and reduce cancer risk in individuals with a history of inflammatory bowel disease.

This research is part of the Cancer Grand Challenges team PROSPECT, a global initiative focused on understanding and preventing cancer. The study was supported by grants from the National Institutes of Health (NIH), Cancer Research UK, the French National Cancer Institute, and the Bowelbabe Fund for Cancer Research UK.

The next steps involve refining our understanding of the specific epigenetic changes involved and exploring potential therapeutic targets. Clinical trials will be necessary to evaluate the safety and efficacy of any interventions aimed at modulating AP-1 activity or reversing the epigenetic memory of inflammation. Ongoing surveillance and monitoring of individuals with a history of chronic gut inflammation will also be crucial to identify those at highest risk and to track the long-term impact of these epigenetic changes.